ArticleGenome research2026
Cell type-specific gene regulatory atlas prioritizes drug targets and repurposable medicines in Alzheimer's disease.
Yunxiao Ren, Ming Hu, Yang E Li, Andrew A Pieper, Jeffrey Cummings, Feixiong Cheng
Abstract read
In one paragraphArticle in Genome research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Yunxiao RenCleveland Clinic Genome Center, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Ming HuDepartment of Quantitative Health Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio 44195, USA.
Yang E LiDepartment of Neurosurgery and Genetics, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Andrew A PieperDepartment of Psychiatry, Case Western Reserve University, Cleveland, Ohio 44106, USA.
Jeffrey CummingsChambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, Kirk Kerkorian School of Medicine, University of Nevada-Las Vegas, Las Vegas, Nevada 89154, USA.
Feixiong ChengCleveland Clinic Genome Center, Cleveland Clinic Research, Cleveland Clinic, Cleveland, Ohio 44195, USA; chengf@ccf.org.
Funding
Translational and Therapeutics CoreP30AG072959 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI JAGAN AYYAPPAN PILLAI · 2021 to 2026
$23.9MRenewal of Centers of Biomedical Research Excellence (COBRE) (Phase 2) CNTN - ResubmissionP20GM109025 · NIGMS · CLEVELAND CLINIC FOUNDATION · PI Robert J. Fox, Jefferson Kinney · 2015 to 2026
$22.8MRisk and Resilience, Clinical presentation, and Biomarker Profiles of Chronic Traumatic Encephalopathy and Related Dementias: The DIAGNOSE CTE Research Project IIR01NS139383 · NINDS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI Michael Alosco, Nicholas Ashton · 2024 to 2026
$9.3MEndophenotype Network-based Approaches to Prediction and Population-based Validation of In Silico Drug Repurposing for Alzheimer's DiseaseR01AG066707 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI Feixiong Cheng · 2020 to 2026
$4.9MTREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for Alzheimers DiseaseR01AG076448 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI Feixiong Cheng, Li Gan · 2022 to 2026
$4.0MAlzheimer's MultiOme Data Repurposing: Artificial Intelligence, Network Medicine, and Therapeutics DiscoveryU01AG073323 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI BEKRIS, LYNN, CHENG, FEIXIONG · 2021 to 2025
$4.0MAlzheimer's Clinical Trial InnOvatioN (ACTION) InitiativeR35AG071476 · NIA · UNIVERSITY OF NEVADA LAS VEGAS · PI CUMMINGS, JEFFREY L. · 2021 to 2025
$2.9MAlzheimer's Disease and Related Dementia-like Sequelae of SARS-CoV-2 Infection: Virus-Host Interactome, Neuropathobiology, and Drug RepurposingRF1AG082211 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI CHENG, FEIXIONG, PIEPER, ANDREW A · 2023 to 2023
$2.4MCharacterize neuronal and glial cell-specific vulnerability to proteinopathies in Alzheimer's disease using multimodal single-nuclei genomic and epigenomic approachesR01AG082118 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI BONAKDARPOUR, BORNA, CHENG, FEIXIONG · 2023 to 2025
$2.4MDark GPCR signaling underlying the Microbiome-Gut-Brain Axis for Alzheimer's Disease and Related DementiaRF1NS133812 · NINDS · CLEVELAND CLINIC LERNER COM-CWRU · PI BROWN, JONATHAN MARK, CHENG, FEIXIONG · 2023 to 2023
$2.3MMicroglial Activation and Inflammatory Endophenotypes Underlying Sex Differences of Alzheimer’s DiseaseR01AG084250 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI Feixiong Cheng, Justin D. Lathia · 2023 to 2026
$2.2MA Multimodal, Multiscale and Multistage Systems Biology (M3SB) Infrastructure for Precision Medicine in Alzheimer’s Disease and LongevityR01AG092591 · NIA · CLEVELAND CLINIC LERNER COM-CWRU · PI Feixiong Cheng, ANDREW J SAYKIN · 2025 to 2026
$1.6MNIA NIH HHS P30 AG072959NIA NIH HHS R01 AG066707NIA NIH HHS R01 AG076448NIA NIH HHS R01 AG082118NIA NIH HHS R01 AG084250NIA NIH HHS R01 AG092462NIA NIH HHS R01 AG092591NIA NIH HHS R21 AG083003NIA NIH HHS R25AG083721-01NIA NIH HHS R33 AG083003NIA NIH HHS R35 AG071476NIA NIH HHS RF1 AG082211NIA NIH HHS U01 AG073323NIGMS NIH HHS P20 GM109025NINDS NIH HHS R01 NS139383NINDS NIH HHS RF1 NS133812
6 · The paper itselfAbstract
Alzheimer's disease (AD) is a complex and poorly understood neurodegenerative disorder that lacks sufficiently effective treatments. Computational and integrative analyses that leverage multiomic data provide a promising strategy to uncover disease mechanisms and identify therapeutic opportunities. Here, we develop a cell type-specific regulatory atlas of the human middle temporal gyrus via leveraging single-nucleus RNA-seq (1,197,032 nuclei) and ATAC-seq (740,875 nuclei) data sets from 84 donors across four stages of AD neuropathological change (ADNC). We observe differential gene expression for six major cell types intensified at severe ADNC. Integrating peak-to-gene linkages and motif enrichment analyses, we reconstruct transcription factor (TF)-target gene networks across six major brain cell types. By integrating genome-wide association study (GWAS) loci with cell type-specific
Indexed as
Alzheimer DiseaseDrug RepositioningGene Regulatory NetworksGene Expression RegulationGenome-Wide Association StudyHumansTranscription FactorsTranscription Factors
Identifiers
PMID41565468
PMCPMC12951949
What Socratic holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390